165 related articles for article (PubMed ID: 37859597)
1. Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.
Vayani OR; Kaufman ME; Moore K; Chennakesavalu M; TerHaar R; Chaves G; Chlenski A; He C; Cohn SL; Applebaum MA
Pediatr Blood Cancer; 2024 Jan; 71(1):e30735. PubMed ID: 37859597
[TBL] [Abstract][Full Text] [Related]
2. Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.
Vayani OR; Kaufman ME; Moore K; Chennakesavalu M; TerHaar R; Chaves G; Chlenski A; He C; Cohn SL; Applebaum MA
bioRxiv; 2023 Sep; ():. PubMed ID: 37693610
[TBL] [Abstract][Full Text] [Related]
3. 5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma.
Applebaum MA; Barr EK; Karpus J; West-Szymanski DC; Oliva M; Sokol EA; Zhang S; Zhang Z; Zhang W; Chlenski A; Salwen HR; Wilkinson E; Dobratic M; Grossman RL; Godley LA; Stranger BE; He C; Cohn SL
Clin Cancer Res; 2020 Mar; 26(6):1309-1317. PubMed ID: 31852832
[TBL] [Abstract][Full Text] [Related]
4. T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature.
Kaufman ME; Vayani OR; Moore K; Chlenski A; Wu T; Chavez G; Lee SM; Desai AV; He C; Cohn SL; Applebaum MA
bioRxiv; 2023 Jun; ():. PubMed ID: 37425883
[TBL] [Abstract][Full Text] [Related]
5. 5-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma.
Chennakesavalu M; Moore K; Chaves G; Veeravalli S; TerHaar R; Wu T; Lyu R; Chlenski A; He C; Piunti A; Applebaum MA
JCO Precis Oncol; 2024 Jan; 8():e2300297. PubMed ID: 38295320
[TBL] [Abstract][Full Text] [Related]
6. Combination of tumor necrosis factor-α and epidermal growth factor induces the adrenergic-to-mesenchymal transdifferentiation in SH-SY5Y neuroblastoma cells.
Huang Y; Tsubota S; Nishio N; Takahashi Y; Kadomatsu K
Cancer Sci; 2021 Feb; 112(2):715-724. PubMed ID: 33277754
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal impacts of telomerase activity and ADRN/MES differentiation state in neuroblastoma tumor biology.
Yu EY; Zahid SS; Aloe S; Falck-Pedersen E; Zhou XK; Cheung NV; Lue NF
Commun Biol; 2021 Nov; 4(1):1315. PubMed ID: 34799676
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel.
van Wezel EM; van Zogchel LMJ; van Wijk J; Timmerman I; Vo NK; Zappeij-Kannegieter L; deCarolis B; Simon T; van Noesel MM; Molenaar JJ; van Groningen T; Versteeg R; Caron HN; van der Schoot CE; Koster J; van Nes J; Tytgat GAM
JCO Precis Oncol; 2019; 3():. PubMed ID: 34036221
[TBL] [Abstract][Full Text] [Related]
9. Deep analysis of neuroblastoma core regulatory circuitries using online databases and integrated bioinformatics shows their pan-cancer roles as prognostic predictors.
Jahangiri L; Pucci P; Ishola T; Pereira J; Cavanagh ML; Turner SD
Discov Oncol; 2021 Nov; 12(1):56. PubMed ID: 35201514
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors.
Westerhout EM; Hamdi M; Stroeken P; Nowakowska NE; Lakeman A; van Arkel J; Hasselt NE; Bleijlevens B; Akogul N; Haneveld F; Chan A; van Sluis P; Zwijnenburg D; Volckmann R; van Noesel CJM; Adameyko I; van Groningen T; Koster J; Valentijn LJ; van Nes J; Versteeg R
Cancer Res; 2022 Feb; 82(3):484-496. PubMed ID: 34853072
[TBL] [Abstract][Full Text] [Related]
11. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma.
van Groningen T; Akogul N; Westerhout EM; Chan A; Hasselt NE; Zwijnenburg DA; Broekmans M; Stroeken P; Haneveld F; Hooijer GKJ; Savci-Heijink CD; Lakeman A; Volckmann R; van Sluis P; Valentijn LJ; Koster J; Versteeg R; van Nes J
Nat Commun; 2019 Apr; 10(1):1530. PubMed ID: 30948783
[TBL] [Abstract][Full Text] [Related]
12. ASCL1 characterizes adrenergic neuroblastoma via its pioneer function and cooperation with core regulatory circuit factors.
Wang L; Tan TK; Kim H; Kappei D; Tan SH; Look AT; Sanda T
Cell Rep; 2023 Dec; 42(12):113541. PubMed ID: 38060444
[TBL] [Abstract][Full Text] [Related]
13. Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.
Lodrini M; Graef J; Thole-Kliesch TM; Astrahantseff K; Sprüssel A; Grimaldi M; Peitz C; Linke RB; Hollander JF; Lankes E; Künkele A; Oevermann L; Schwabe G; Fuchs J; Szymansky A; Schulte JH; Hundsdörfer P; Eckert C; Amthauer H; Eggert A; Deubzer HE
Clin Cancer Res; 2022 May; 28(9):1809-1820. PubMed ID: 35247920
[TBL] [Abstract][Full Text] [Related]
14. Association of high-risk neuroblastoma classification based on expression profiles with differentiation and metabolism.
Kimura S; Sekiguchi M; Watanabe K; Hiwatarai M; Seki M; Yoshida K; Isobe T; Shiozawa Y; Suzuki H; Hoshino N; Hayashi Y; Oka A; Miyano S; Ogawa S; Takita J
PLoS One; 2021; 16(1):e0245526. PubMed ID: 33465163
[TBL] [Abstract][Full Text] [Related]
15. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
[No Abstract] [Full Text] [Related]
16. Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma.
Su Y; Wang L; Jiang C; Yue Z; Fan H; Hong H; Duan C; Jin M; Zhang D; Qiu L; Cheng X; Xu Z; Ma X
BMC Cancer; 2020 Feb; 20(1):102. PubMed ID: 32028911
[TBL] [Abstract][Full Text] [Related]
17. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.
Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H
J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the developmental origin of neuroblastoma: an overview.
Ponzoni M; Bachetti T; Corrias MV; Brignole C; Pastorino F; Calarco E; Bensa V; Giusto E; Ceccherini I; Perri P
J Exp Clin Cancer Res; 2022 Mar; 41(1):92. PubMed ID: 35277192
[TBL] [Abstract][Full Text] [Related]
19. RBM39 degrader invigorates natural killer cells to eradicate neuroblastoma despite cancer cell plasticity.
Singh S; Fang J; Jin H; Van de Velde LA; Wu Q; Cortes A; Morton CL; Woolard MA; Quarni W; Steele JA; Connelly JP; He L; Thorne R; Turner G; Confer T; Johnson M; Caufield WV; Freeman BB; Lockey T; Pruett-Miller SM; Wang R; Davidoff AM; Thomas PG; Yang J
bioRxiv; 2024 Mar; ():. PubMed ID: 38585889
[TBL] [Abstract][Full Text] [Related]
20. Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity.
D'Amico S; Tempora P; Gragera P; Król K; Melaiu O; De Ioris MA; Locatelli F; Fruci D
Front Immunol; 2023; 14():1268645. PubMed ID: 37849756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
